arsenazo-iii and Pituitary-Neoplasms

Thyrotropin-releasing hormone (TRH) may act to stimulate prolactin secretion by increasing the intracellular free Ca2+ concentration. This notion is supported by the finding that TRH acutely enhances 45Ca2+ efflux from pituitary cells which may reflect alterations in Ca2+ influx or efflux, or both. To differentiate among these possibilities, we measured loss and uptake of nonradioactive Ca2+ by GH3 cells, a cloned strain of rat pituitary cells that produce prolactin, during TRH action using the metallochromic indicator arsenazo III. Cells were perfused in medium containing 2.8 microM Ca2+ and nonradioactive Ca2+ was measured in the perfusion effluent. Under these conditions, there was a sustained loss of Ca2+ from the cells for at least 30 min. TRH caused a transient, marked increase in the amount of Ca2+ released into the medium which occurred in parallel with enhancement in 45Ca2+ efflux and stimulation of prolactin secretion. There was no measurable decrease in Ca2+ concentration in the medium at the onset of the TRH effect which would have been consistent with Ca2+ influx into the cells. Furthermore, an identical response to TRH was observed in cells perfused with medium containing 50 microM verapamil, an agent which blocks Ca2+ influx. In static incubations performed in parallel, TRH caused a decrease in total cellular Ca2+ of 23 +/- 5%. These data provide direct evidence that TRH causes loss of Ca2+ from GH3 cells without causing measurable Ca2+ uptake and support the contention that TRH acts by mobilizing Ca2+ from a sequestered cellular pool (or pools).

Topics: Animals; Arsenazo III; Biological Transport, Active; Calcium; Cell Line; Kinetics; Neoplasms, Experimental; Pituitary Neoplasms; Rats; Thyrotropin-Releasing Hormone